Results 91 to 100 of about 60,176 (280)

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Effects of Recombinant Erythropoietin on Breast Cancer-Initiating Cells

Neoplasia: An International Journal for Oncology Research, 2007
BACKGROUND: Cancer anemia causes fatigue and correlates with poor treatment outcome. Erythropoietin has been introduced in an attempt to correct these defects.
Tiffany M. Phillips, Kwanghee Kim, Erina Vlashi, William H. McBride, Frank Pajonk   +4 more
doaj   +1 more source

Feline primary erythrocytosis: a multicentre case series of 18 cats [PDF]

, 2018
A retrospective multicentre case series of feline primary erythrocytosis (PE) was evaluated. The aim was to gain better understanding of disease presentation and progression to guide management and prognostication. Case records were assessed for evidence
Balazs Szladovits, Barbara Glanemann, Hannah Darcy, Isuru Gajanayake, Katherine Simpson, Mayank Seth, McLornan D, Yvonne McGrotty   +7 more
core   +2 more sources

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source

The Cellular Biology of Erythropoietin Receptors

The Oncologist, 2003
Abstract Learning Objectives After completing this course, the reader will be able to: Explain the structure and functions of erythropoietin. Distinguish the multiple activities of erythropoietin in the human body. Recognize the potential role of erythropoietin receptors in targeting
openaire   +2 more sources

Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain

Acta Neuropathologica, 2001
Using immunohistochemistry, expression of erythropoietin (EPO), a hypoxia-inducible neuroprotective factor, and its receptor (EPOR) were investigated in human brain tissue after ischemia/hypoxia. Autopsy brains of neuropathologically normal subjects were compared to those with ischemic infarcts or hypoxic damage.
Siren, A. L., Knerlich, F., Poser, Wolfgang, Gleiter, Christoph H., Bruck, Wolfgang W., Ehrenreich, Hannelore   +5 more
openaire   +3 more sources

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source

Design and Development of a Behaviorally Active Recombinant Neurotrophic Factor

Drug Design, Development and Therapy, 2020
Nicholas J Pekas,1 Jason L Petersen,2,3 Monica Sathyanesan,1,2 Samuel S Newton1,2 1Department of Basic Biomedical Sciences, University of South Dakota Sanford School of Medicine, Vermilion, SD, USA; 2Sioux Falls VA Health Care System, Sioux Falls, SD ...
Pekas NJ, Petersen JL, Sathyanesan M, Newton SS   +3 more
doaj  

Congenital familial erythrocytosis: A case report with literature review

Saudi Journal of Medicine and Medical Sciences, 2015
Familial erythrocytosis is a heterogeneous group of hereditary conditions with an increased total red blood cell volume. The disease occurs in a familial pattern and follows a relatively benign course.
Ishrat H Dar, Showkat H Dar, Muqtasid A Kamili, Mohammad I Quadri, Hardeep S Wazir, Aijaz A Bhat   +5 more
doaj   +1 more source

Hypoxia enhances the tissue protective effect of erythropoietin and its analogues in an endothelial cell injury model [PDF]

, 2015
PO has tissue protective activities in ischemic disease but also has prothrombotic, erythropoietic effects. Carbamylated EPO (CEPO) retains the protective actions without the erythropoietic effects.
Ferns, Gordon, Ghezzi, Pietro, Heikal, Lamia, Mengozzi, Manuela   +3 more
core